Overview

Ferrer Internacional S.A. withdrew its application for a marketing authorisation of Orepaxam for the treatment of pulmonary arterial hypertension.

The company withdrew the application on 11 October 2022.

Orepaxam was developed as a medicine for the treatment of pulmonary arterial hypertension (PAH), a rare blood vessel disorder of the lungs in which the pressure in the pulmonary artery (the vessel that leads blood from the heart to the lungs) rises above normal levels. The medicine contains the active substance treprostinil diolamine.

Orepaxam was developed as a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ called Remodulin but there are some differences between the 2 products. Both Remodulin and Orepaxam contain treprostinil but the medicines contain a different salt (diolamine for Orepaxam and sodium for Remodulin). Orepaxam was to be available as prolonged-release tablets to be taken by mouth, while Remodulin is given by injection under the skin or infusion (drip) into a vein.

Orepaxam was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 26 August 2005 for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Treprostinil works in a similar way to prostacyclin, a natural substance that widens blood vessels and stops platelets (blood components) from sticking to each other to form blood clots. These effects lower blood pressure in the pulmonary artery and so improve symptoms of PAH.

The company provided results of four main studies that investigated the effects of Orepaxam when used on its own, or together with other therapies for PAH taken by mouth, in around 1,700 patients. In all the studies, Orepaxam was compared with placebo (a dummy treatment). Three studies looked at changes in exercise capacity measured as the improvement in the distance patients could walk in 6 minutes after 12 or 16 weeks of treatment. The fourth study looked at a delay in disease progression measured by how long it took before symptoms worsened.

The application was withdrawn while the European Medicines Agency was still evaluating the initial information from the company.

As the Agency was still evaluating the initial information from the company, it had not yet made any recommendations.

In its Withdrawal letter: Orepaxam notifying the Agency of the withdrawal of the application, the company stated that it withdrew its application because it was expected that further clinical evidence would be requested, which could not be adequately addressed with the anticipated timeframe.

The company informed the Agency that there are no clinical trials ongoing.

There are no consequences for patients in compassionate use programmes using Orepaxam.

If you are in a compassionate use programme and need more information about your treatment, speak with your doctor.

Questions and answers on the withdrawal of application for the marketing authorisation of Orepaxam (treprostinil diolamine)

Reference Number: EMA/861343/2022

English (EN) (135.23 KB - PDF)

First published:
View

Key facts

Name of medicine
Orepaxam
Active substance
treprostinil diolamine
International non-proprietary name (INN) or common name
treprostinil diolamine
Therapeutic area (MeSH)
Hypertension, Pulmonary
Anatomical therapeutic chemical (ATC) code
B01AC21
EMA product number
EMEA/H/C/005990

Orphan

<p>This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see <a href="/node/69983">Orphan designation</a>.</p>
Marketing authorisation applicant
Ferrer Internacional S.A.
Withdrawal of application
11/10/2022

All Documents

Withdrawal letter: Orepaxam

English (EN) (21.68 KB - PDF)

First published:
View
This page was last updated on

Share this page